Raymond James & Associates Has $4.99 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Raymond James & Associates boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,915 shares of the medical research company’s stock after buying an additional 1,179 shares during the period. Raymond James & Associates’ holdings in Bio-Rad Laboratories were worth $4,990,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. UMB Bank n.a. lifted its holdings in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after buying an additional 45 shares during the period. Capital Advisors Ltd. LLC increased its stake in Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 62 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Bio-Rad Laboratories in the first quarter valued at approximately $51,000. Headlands Technologies LLC bought a new stake in Bio-Rad Laboratories in the second quarter valued at approximately $51,000. Finally, Quarry LP bought a new stake in Bio-Rad Laboratories in the second quarter valued at approximately $59,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on BIO. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 target price for the company. Citigroup upped their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Royal Bank of Canada increased their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research report on Thursday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $391.80.

Bio-Rad Laboratories Stock Up 2.9 %

Shares of BIO stock opened at $368.42 on Friday. The company has a market capitalization of $10.27 billion, a price-to-earnings ratio of -13.48 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $372.27. The firm has a fifty day moving average of $333.99 and a 200-day moving average of $308.47. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.73. The business had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.66%. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.33 earnings per share. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 9.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.